NFKB1 and neoplasm: Ibrutinib irreversibly binds to cysteine residue, C481, in the active site of BTK, thereby inhibiting BTK phosphorylation on T223 and resulting in loss of BTK function, NF-κB inhibition and induction of tumour-cell apoptosis [114].